Literature DB >> 20635285

Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: a case-control study.

Steven L Batki1, Kelly M Canfield, Emily Smyth, Robert Ploutz-Snyder, Robert A Levine.   

Abstract

Comorbid medical illness is common in patients with chronic hepatitis C (HCV) infection and in methadone treatment (MMT) patients, yet little is known about the impact of medical illness on HCV treatment eligibility. Medical illness and HCV treatment eligibility were compared in a case-control study of 80 MMT patients entering an HCV treatment trial and 80 matched non-MMT patients entering HCV treatment in a gastroenterology clinic. 91% of MMT and 85% of non-MMT patients had chronic medical conditions. Despite similar medical severity ratings, a significantly higher proportion (77%) of non-MMT patients were eligible for HCV treatment than were MMT patients (56%) (p<.01). Specific comorbid medical and psychiatric illness led to ineligibility in only 18% of MMT and 16% of non-MMT patients. However, failure to complete the medical evaluation process was significantly (p<.001) more likely to cause ineligibility among MMT patients (19%) than non-MMT patients (0%).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20635285      PMCID: PMC4651622          DOI: 10.1080/10550887.2010.489449

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  51 in total

1.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

2.  Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.

Authors:  Shruti H Mehta; Gregory M Lucas; Lisa B Mirel; Michael Torbenson; Yvonne Higgins; Richard D Moore; David L Thomas; Mark S Sulkowski
Journal:  AIDS       Date:  2006-11-28       Impact factor: 4.177

3.  Treatment of hepatitis C infection in injection drug users.

Authors:  M Backmund; K Meyer; M Von Zielonka; D Eichenlaub
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

4.  Co-occurrence of treatment nonadherence and continued HIV transmission risk behaviors: implications for positive prevention interventions.

Authors:  Seth C Kalichman
Journal:  Psychosom Med       Date:  2008-06-02       Impact factor: 4.312

5.  Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3.

Authors:  Mitchell L Shiffman; Anastasios A Mihas; Farida Millwala; Richard K Sterling; Velimir A Luketic; R Todd Stravitz; Arun J Sanyal
Journal:  Am J Gastroenterol       Date:  2007-02-23       Impact factor: 10.864

Review 6.  The medical complications of drug addiction and the medical assessment of the intravenous drug user: 25 years later.

Authors:  C E Cherubin; J D Sapira
Journal:  Ann Intern Med       Date:  1993-11-15       Impact factor: 25.391

7.  Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans.

Authors:  A A Butt; U A Khan; K A McGinnis; M Skanderson; C Kent Kwoh
Journal:  J Viral Hepat       Date:  2007-12       Impact factor: 3.728

8.  Treating hepatitis C in methadone maintenance patients: an interim analysis.

Authors:  Diana L Sylvestre
Journal:  Drug Alcohol Depend       Date:  2002-07-01       Impact factor: 4.492

Review 9.  Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

Authors:  Leonard B Seeff; Jay H Hoofnagle
Journal:  Clin Liver Dis       Date:  2003-02       Impact factor: 6.126

10.  Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.

Authors:  Joseph J Amon; Richard S Garfein; Linda Ahdieh-Grant; Gregory L Armstrong; Lawrence J Ouellet; Mary H Latka; David Vlahov; Steffanie A Strathdee; Sharon M Hudson; Peter Kerndt; Don Des Jarlais; Ian T Williams
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

View more
  5 in total

Review 1.  Colocalization in Hepatitis C Virus Infection Care: The Role of Opioid Agonist Therapy Clinics.

Authors:  Lynn E Taylor
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-07-21

2.  Viral hepatitis among drug users in methadone maintenance: associated factors, vaccination outcomes, and interventions.

Authors:  David C Perlman; Ashly E Jordan; Courtney McKnight; Christopher Young; Kevin L Delucchi; James L Sorensen; Don C Des Jarlais; Carmen L Masson
Journal:  J Addict Dis       Date:  2014

Review 3.  Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.

Authors:  Brianna L Norton; Matthew J Akiyama; Philippe J Zamor; Alain H Litwin
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

4.  GRK5 Is Associated with the Regulation of Methadone Dosage in Heroin Dependence.

Authors:  Sheng-Chang Wang; Ren-Hua Chung; Hsiang-Wei Kuo; Tung-Hsia Liu; Chiu-Ping Fang; Shu Chih Liu; Chia-Chen Liu; Hsiao-Hui Tsou; Andrew C H Chen; Yu-Li Liu
Journal:  Int J Neuropsychopharmacol       Date:  2018-10-01       Impact factor: 5.176

5.  Hepatitis C virus infection influences the S-methadone metabolite plasma concentration.

Authors:  Shiow-Ling Wu; Sheng-Chang Wang; Hsiao-Hui Tsou; Hsiang-Wei Kuo; Ing-Kang Ho; Sheng-Wen Liu; Ya-Ting Hsu; Yao-Sheng Chang; Yu-Li Liu
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.